Conditions: Chronic Obstructive Pulmonary Disease
Keywords: Chronic Obstructive Pulmonary Disease Indacaterol Salmeterol/fluticasone propionate
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 581
Healthy volunteers: no

Brief summary:
The purpose of this study is to compare the effectiveness and safety of indacaterol with salmeterol /fluticasone propionate treatment in patients with moderate chronic obstructive pulmonary disease who, on entry to the study are being treated with salmeterol /fluticasone propionate.

Detailed description:

Arms:
arm 1: Indacaterol 150 mcg once daily (o.d.) delivered via the Novartis single dose dry power inhaler (SDDPI) (Onbrez® Breezhaler®) arm 2: Salmeterol 50 mcg /fluticasone propionate 500 mcg for inhalation delivered via a proprietary multi dose dry powder inhaler (MDDPI) device (Seretide® Accuhaler®) twice daily (b.i.d.)

Interventions: intervention 1: Indacaterol intervention 2: Salmeterol
Intervention descriptions: intervention 1: Indacaterol is delivered via a SDDPI. intervention 2: Salmeterol/fluticasone is delivered via a MDDPI

Protocol document: